Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

OBJECTIVES: To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in China. METHODS: In this phase 3, open-label extension period, eligible completers of study BEL113750 (NCT01345253) received intravenous belimumab 10 mg/kg monthly for ≤6 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fengchun, Zheng, Jie, Li, Yang, Wang, Guochun, Wang, Mingjun, Su, Yin, Gu, Jieruo, Li, Xingfu, Bass, Damon, Chu, Myron, Curtis, Paula, DeRose, Kathleen, Kurrasch, Regina, Lowe, Jenny, Meizlik, Paige, Roth, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014060/
https://www.ncbi.nlm.nih.gov/pubmed/35428697
http://dx.doi.org/10.1136/rmdopen-2021-001669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014060/
https://www.ncbi.nlm.nih.gov/pubmed/35428697
http://dx.doi.org/10.1136/rmdopen-2021-001669

Ejemplares similares